Core Insights - The research team led by Professor Xiao Yibei from China Pharmaceutical University has revealed a new immune mechanism by which bacteria resist phage infections, providing insights for the development of related drugs [1][2] Group 1: Immune Mechanism Discovery - Bacteria can suppress phage infection and propagation, challenging the previous belief that only higher organisms possess immune systems [1] - The study is based on the CRISPR-Cas system, which is a gene-editing technology that can cut genetic material at specific locations [1][2] Group 2: ATP Metabolism and Phage Resistance - The new mechanism involves depleting ATP, the energy factor within bacteria, which slows down the phage's ability to replicate [2] - Bacteria convert ATP into toxic ITP, which hinders phage replication due to insufficient energy [2] - A hydrolytic enzyme within bacteria further degrades ITP, allowing bacteria to detoxify and eventually recover after clearing phages during a 'dormant' state [2] Group 3: Implications for Future Research - The discovery highlights the intrinsic link between bacterial immunity and metabolic processes, enhancing the scientific community's understanding of gene-editing technologies [2] - This research provides important insights for the future development of anti-infection drugs [2]

Core Viewpoint - Fudan University has made significant breakthroughs in the medical field, including the discovery of a new treatment target for Parkinson's disease and the upcoming launch of early screening and diagnostic testing for Alzheimer's disease, supported by AI computing power from the CFFF platform in collaboration with Alibaba Cloud [1][3]. Group 1: Breakthroughs in Alzheimer's and Parkinson's Disease - The research team led by Professor Yu Kintai has achieved a 15-year early prediction of Alzheimer's disease risk with over 98.7% accuracy, published in the journal Nature [3][5]. - The team has identified a new treatment target for Parkinson's disease and utilized AI to screen potential drugs, with findings published in top international journals such as Cell and Nature [3][5]. Group 2: CFFF Platform and AI Integration - The CFFF platform, launched in 2023, integrates advanced computing clusters and AI technologies, enabling researchers to process large datasets more efficiently than traditional methods [3][4]. - The platform supports over 1,000 parallel intelligent computations and facilitates the training of large models with billions of parameters, significantly enhancing research capabilities [3][4]. Group 3: Efficiency Improvements in Research - The use of AI and innovative data-driven methods has allowed the research team to analyze over 6,361 cerebrospinal fluid proteins, identifying five key proteins that improve diagnostic accuracy to 98.7% [4][5]. - AI technology has accelerated the identification of potential therapeutic targets in Parkinson's disease, completing in five years what would traditionally take decades [5].

Core Viewpoint - UK BioBank emphasizes the importance of its database for global health and disease research, particularly in light of recent restrictions imposed by the NIH on data access for researchers in China and other countries [1][4][5]. Group 1: Impact of NIH Restrictions - The NIH has prohibited access to its controlled databases, including the SEER database, for researchers from specific countries, including China, effective April 4, 2025 [4][8]. - The SEER database is crucial for cancer research, covering data from 48% of the U.S. population, and has been relied upon by approximately 75% of cancer epidemiology papers published by Chinese scholars [9][10]. - The restrictions have raised concerns about a potential "cold war" in scientific research, with fears that other databases may follow suit in limiting access for Chinese researchers [5][10]. Group 2: Need for Domestic Data Sharing - Chinese research institutions must enhance their capabilities and promote scientific data sharing to avoid being significantly hindered by international restrictions [6][10]. - The current state of biomedical research in China shows a significant reliance on foreign databases, with 99% of pharmaceuticals and 100% of databases not being domestically sourced [13][14]. - Since 2004, China has made efforts to build national scientific data sharing platforms, but challenges remain in the implementation and effectiveness of these initiatives [15][17]. Group 3: Challenges in Data Sharing - There is a systemic lack of focus on scientific data development in China, with many efforts being limited to small teams rather than a cohesive national strategy [17][18]. - The reliance on foreign databases in educational institutions hampers the development of domestic data products, which, despite having competitive potential, struggle due to low user engagement [18][19]. - The phenomenon of "false sharing" is prevalent, where databases are claimed to be open but are not genuinely accessible, leading to a cycle of underutilization and slow development [21][22].